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Abstract
For more than four decades, scientists and engineers are trying to miniaturise dialysis 
machines to make them wearable. There are many reasons for that—from increased bio-
compatibility and cost-efficiency to longer life expectancy and higher quality of life. That 
can be achieved by continuous blood treatment like in natural kidneys, which softly filter 
blood for 168 h a week when hemodialysis does that quickly—for approximately 20 h a 
week, which affects the organism in a bad way. Along with that, during hemodialysis, the 
patient must be near the dialysis machine, in contrary to wearable apparatus that can be 
carried anywhere. To achieve these advantages, dialysis fluid regeneration system must 
be developed, and it is a problem to be solved in the next few years. In this chapter, we 
describe current prototypes of wearable artificial kidneys, their design principles and 
results of our investigations.
Keywords: wearable health, dialysis, wearable artificial kidney, personalised medicine, 
dialysate regeneration
1. Introduction
In case of renal failure (RF), products of metabolism remain in blood and cells, and excessive 
fluid is not removed from the body. There are two types of RF—acute renal failure (ARF), 
which is often reversible with proper treatment, and chronic kidney disease (CKD), which is 
usually irreversible. The causes of CKD are diverse, most often diabetes mellitus, high blood 
pressure, glomerulonephritis, and so on. In Figure 1, incidence and accidence of terminal 
stage of CKD in several countries is shown.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The only way of adequate treatment of CKD is kidney transplantation. Renal replacement 
therapy (RRT) is an artificial blood purification process that is achieved by several methods 
that do not cure kidney failure but keep living organism of patients for years while there 
will be a possibility to carry out a kidney transplantation. ARF is also treated via artificial 
blood purification. Artificial blood purification (or dialysis) is a process of removing metabo-
lites and excess fluid from patient’s organism. Dialysis does not replace all kidney functions 
(e.g., endocrine function), and in some cases, patients require additional therapy (e.g., hor-
monal). Clinical tasks of renal replacement therapy are to purify the body, remove excess 
fluid (Ultrafiltration, or UF) and maintain electrolyte balance (concentration of K+, Na+, Ca2+ 
ions, etc.).
Methods of dialysis blood purification are divided into two categories: extracorporeal 
methods (hemodialysis or HD) and intracorporeal methods (peritoneal dialysis or PD). 
Extracorporeal methods perform blood pumping through a dialyser, in which the metabolic 
products pass across membranes into dialysate solution due to diffusion and convection. 
In case of intracorporeal methods, peritoneal (abdominal) cavity represents itself a semi-
permeable membrane across which the mass transfer is carried out due to diffusion and 
osmosis. For HD and PD, different dialysis solutions are used. Generally, dialysate consists 
of highly purified water, sodium, potassium, magnesium, calcium and chlorine ions in con-
centrations close to their concentrations in the blood. In case of PD, dialysis fluid must also 
contain an osmotic substance like glucose or icodextrin. There are other differences in pH, 
buffers, and so on.
Since the peritoneal membrane has a thickness of up to 1000 μm, the efficiency of peritoneal 
dialysis is significantly lower than the efficiency of hemodialysis because dialyser membranes 
Figure 1. Incidence and prevalence of terminal stage CKD in the world by USRDS Atlas 2013 [1].
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are about 200 μm thick. Therefore, renal replacement therapy should be carried out continu-
ously: abdominal cavity must be filled with a dialysis solution for long periods, where it is 
saturated with metabolites within a few hours, after which solution is replaced with fresh one. 
Continuity is the main advantage of peritoneal dialysis, as the procedure for purifying the 
blood proceeds more physiologically, the cardiovascular system experiences less additional 
stresses, and the residual function of the kidneys remains longer.
Comparison between HD and PD is presented in Table 1.
For more than 40 years, scientists and engineers are developing technologies that will enable 
to create a wearable artificial kidney (WAK). WAK has potential to overcome the negative 
sides of existing methods of RRT. There are some advantages of WAK over HD:
• increasing patient’s mobility due to the reduction of its size and weight;
• adjusting blood purification to human physiology (metabolite elimination rate is closer to 
metabolite production rate);
• reduction of water consumption (2l of dialysate per one procedure vs. 120–150 l for 
hemodialysis);
• cost reduction (~€ 45,000 annually using WAK [2] vs ~€ 59,600 annually for continuous 
ambulatory peritoneal dialysis [3]);
• and the following advantages over continuous ambulatory peritoneal dialysis:
• lowering frequency of peritonitis due to rare dialysate exchange (once a day);
• gaining life quality due to the ability to use WAK at work or while travelling;
• reduction of water consumption (2 l of dialysate vs 8 l for 1 day of CAPD).
Dialysis type Pros Cons
Peritoneal dialysis Keep residual kidney function 
longer
Home dialysis
Dialysis for patients with low 
mass index
Fewer amounts of dialysate are 
used (cheaper method)
Necessity of peritoneal catheter implantation 2 weeks before 
the procedures start
Existing solutions degrade peritoneal membrane within 
several years (5+)
Passive source of glucose, it is necessary to monitor the 
intake of carbohydrates
Hemodialysis Dialysis takes 3–4 h for 3 days Rigid schedule of procedures
Spent time: about 20 h per week
Necessity to create a vascular access
Expensive method (up to 85 k€/year/patient)
Table 1. Comparison between HD and PD.
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2. WAK design principles
WAK must comply with several requirements, including:
• safety and biocompatibility (WAK must be equipped with temperature, volume, pH, ionic 
solution sensors, and must have a system for bacterial contamination prevention);
• ease of use (the must be light and ergonomic);
• reliability (the device must function for a long period);
• availability (use of the device should be cheaper than traditional PTA methods);
• continuous power supply (the apparatus must provide continuous operation from the bat-
tery for at least 8 h);
• portability or implantability (the device should not significantly reduce patient mobility);
• elimination of substances normally removed by the kidneys (the apparatus should provide 
an adequate level and speed of removal of uremic toxins). The history of WAK development 
shows that HD was chosen as the major method. However, PD seems to be a more promising 
method for a WAK. Comparison between PD- and HD-based WAKs is presented in Table 2.
For the last several years, PD is chosen as the main method for WAK development in Europe. 
Typical schemes of WAKs are presented in Figure 2.
Implementation of HD as a base for WAK development is connected to the necessity of anti-
coagulant infusion to prevent blood clotting in the dialyser. Besides that in case of HD, tubing 
Dialysis type/
characteristics
WAK
PD-based HD-based
Weight and dimensions 2.5…5 kg, waist bag, shoulder bag or backpack
Usage Home dialysis, workplace dialysis, nocturnal dialysis, 24/7 
dialysis
Short day dialysis, nocturnal 
home dialysis
Preparative operations Peritoneal catheter implantation Arteriovenous fistula 
formation
Eliminated substances Small, medium and large molecules removal Small and medium molecules 
removal
Infection risk Peritonitis possible if solution changed frequently Blood infection possible
Used with Osmotic agent (glucose/dextrose/icodextrin/amino acids) Anticoagulant (heparin)
Annual Cost ~€ 45,000 [3]
Table 2. Comparison between PD- and HD-based WAKs.
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sets must have a dialyzer and an air trap, while PD-based WAK can avoid using such ele-
ments. HD-based WAKs must also have means to fix blood catheters so that they do not dis-
connect from blood vessels due to physical activity. Therefore, the usage of HD-based WAK 
is possible only in clinics. Conversely, WAK on PD basis has potential to be used at home or 
in the office and consequently increase patients’ quality of life.
Special technical aspects of PD-based WAK are connected to the necessity of keeping the ini-
tial concentration of osmotic agent in dialysis fluid during artificial blood purification.
Another aspect of WAKs is the method of ultrafiltration. Particularly, ultrafiltration in dialysis 
regeneration units on HD basis requires two peristaltic pumps to create transmembrane pres-
sure between blood and dialysate compartments of the dialyser. In case of PD-based WAK, 
drainage of excess fluid occurs when spent dialysate exits patients’ body and technically only 
one peristaltic pump is needed (Figure 2).
3. Dialysis regeneration methods
Regeneration of spent dialysate in WAK occurs in dialysis regeneration unit; its structure can 
be different, as it can be seen in Figure 3. Ideal WAK must eliminate all metabolites from spent 
dialysis solution, but this is difficult to implement and validate. It means that dialysis fluid 
that comes out of dialysis regeneration unit must be chemically equal to fresh dialysis fluid. 
However, at the current stage of WAK evolution, this cannot be achieved. In these conditions, 
we can outline substances that are crucial to being eliminated from the dialysis fluid. They 
are urea, creatinine, uric acid, phosphates, p-cresol, and potassium. An important aspect of 
dialysis regeneration is maintaining an ionic compound of dialysis fluid, including concentra-
tions of Ca2+, Mg+, K+, Cl–.
Sorption is the most widespread method for eliminating a wide range of metabolites. This 
method is easy to implement, but its urea and other small molecules elimination capability is 
poor, and therefore it must be combined with effective urea removal method. Research and 
development of new sorbents can increase dialysis efficiency and possibly make WAK usage 
cheaper. There are several well-known methods for urea elimination.
Figure 2. Typical WAK schemes based on a) peritoneal dialysis (AWAK Technologies), b) hemodialysis (nanodialysis); 
PP—peristaltic pump, DRU—dialysate regeneration unit, PC—peritoneal cavity, UF—ultrafiltrate, OA—osmotic agent.
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1.  Enzymatic method is using animal- or plant-derived urease ferment to hydrolyse urease 
and reduce it to carbon dioxide and ammonia; its combination with sorption is used in 
many WAK prototypes. In our work, we extracted a plant-derived enzyme from jack beans. 
For the experimental verification, a sorption column was constructed (Figure 4 top left). 
The column was tested on a model solution, which consisted of peritoneal dialysis solution 
(1 l), urea (~36 mmol), creatinine (~820 mmol/l), uric acid (~700 mmol/l). Model solution cir-
culated through the column with use of a peristaltic pump with a flow speed of 100 ml/min. 
Metabolites’ and ions concentrations were measured each hour for 8 hours. Experimental 
results are presented in Figures 4 and 5. After 8 h, this unit eliminated 7.15 g of urea, 2.08 g 
of creatinine and 0.4 g of uric acid.
The advantage of this method is its ease of use. Expendable materials, in this case, consist of 
a tubing set with sorption element that can be easily replaced by the patient. Drawbacks of 
the method are: complexity of storage and preparation of immobilised urease (up to 1 month 
at 4°C), high cost of the method (expensiveness of zirconium phosphate), presence of alu-
minium in the dialysis solution, the short lifetime of the sorption element (4–6 h) as well as an 
increase of pH, that leads to necessity of buffers infusion.
Figure 3. Types of dialysis regeneration units.
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The electrochemical method uses electrolysers with special electrodes to electrolyse urea and 
other metabolites but produces by-products, which can be removed by activated carbons
Urea can be oxidised either directly on the anode (Eq. (1)) [4, 5] or in solution by interact-
ing with the hypochlorite ion released at the anode (Eqs. (2)–(4)). However, toxic chlorine-
containing compounds and free chlorine can accumulate in solution during electrolysis. Free 
chlorine is formed because of the interaction of the chlorine ion with water.
  ( NH 2 ) 2  CO +  H 2  O →  N 2 ↑ +  CO 2 ↑ + 6  H + + 6  e − (1)
  2  Cl −  →  Cl 2 ↑ + 2  e − (2)
  Cl 2 +  H 2  O → HOCl + HCl (3)
  ( NH 2 ) 2  CO + 3  OCl −  →  N 2 ↑ + 3  CO 2 ↑ + 3  Cl − + 2  H 2  O (4)
The main requirement for the electrolysis of urea is the choice of an effective and safe electro-
catalyst. Studies of various electrode materials have shown that urea can be electrochemically 
Figure 4. Top left—Sorption column structure: Top right—Urea concentration dynamics; bottom left—Creatinine 
concentration dynamics; top right—Uric acid concentration dynamics.
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oxidised in a neutral medium using catalysts made of noble metals such as Ru-TiO2, Ti-Pt, Ti- (Pt-Ir) etc. However, the high cost of such materials is a significant obstacle to their wide 
practical application.
The possibility of electrochemical urea oxidation on electrodes made of platinum group met-
als was investigated. To determine the rate of urea removal, depending on the type of elec-
trode, a series of experiments were performed with the following parameters: current density 
5 mA/cm2; initial urea concentration 30 ± 2 mmol/l; perfusion rate 100 ml/min; the distance 
between electrodes is 1 mm. As an object of study, next electrode types were chosen: graphite; 
platinum, electrochemically deposited on titanium (Ti-Pt(ec)) or by explosion-rolling (Ti-Pt(er)); rhodium, electrochemically deposited on titanium (Ti-Rh(ec)); ruthenium, electrochemically deposited on titanium (Ti-Ru(ec)), as well as electrodes from foamed coal (C(foam)); silicon- carbon films deposited on titanium substrates by vacuum spraying, doped with molybdenum 
(Ti-SiC(Mo)); silicon-diamond films deposited on titanium substrates (Ti-SiC(diam)); platinum sprayed on titanium substrates (Ti-Pt(spray)). The results of the experiment are shown in Table 3. 
Zero removal rate of urea is indicated for electrodes, the coating of which has dissolved before 
the end of the experiment.
Figure 5. pH and ions’ concentration dynamics during dialysate regeneration by urease.
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As can be seen, the highest specific rate of urea elimination occurs on the graphite, Ti-Pt(ed) and Ti-Pt(er) electrodes. The operating time of the platinum-coated electrodes is limited due to the active transition of the coating to the solution: electrodeposited platinum has dissolved within 
40 h; explosion-rolling platinum remained on the substrate for more than 200 h. Lifetime of 
graphite electrodes could not be determined. In connection with this, further investigations 
were carried out on graphite electrodes, since their coating proved to be the most stable.
For these electrodes, a number of additional experiments were carried out, the purpose of 
which was to study the effect of electrolysis on the ionic composition and the acid-base state 
of the solution. Results are presented in Figure 6. Electrolysis on graphite electrodes alkalises 
the solution and affects the ionic composition of the solution. The pH of the solution in 7 h of 
electrolysis is increased from 5.2 to 5.9, and an increase in the concentration of chloride ions 
and chlorine compounds (including sodium hypochlorite) is observed. In the course of the 
experiment, there was also a slight decrease in the calcium concentration, which is probably 
due to the formation of calcium hydroxide on the cathode surface. From the results obtained, 
it follows that the main advantage of the electrochemical method is the elimination of urea, 
but at the same time, electrolysis affects the acid-base state of the solution and its ionic com-
position. To eliminate this disadvantage, it is necessary to apply a post-treatment solution, 
namely sorption columns with activated carbon.
However, research and development of other perspective electrode materials (i.e. graphite 
and other carbon materials) is in progress.
2.  Thermolysis is heating spent dialysate to the temperature of urea decomposition (around 
150°C). This method cannot be used in WAK because of high-energy usage, and difficult to use 
even in the stationary setting because of many thermolysis by-products and caramelisation of 
glucose contained in the dialysate. In case of WAK usage, it is only usable in HD conditions.
Material Urea elimination rate, mg/g Anode surface 
area, cm2
Specific urea elimination rate, 
mg/cm2·h
Graphite 274 150 1.83
Ti-Pt(ec) 73 150 0.49
Ti-Pt(er) 70 150 0.47
Ti-SiC(diam) 32 100 0.32
Ti-Rh(ec) 30 100 0.30
C(foam) 20 100 0.20
Ti-Ru(ec) 0 100 0
Ti-SiC(Mo) 0 50 0
Ti-Pt(spray) 0 18 0
Table 3. Urea elimination rates by electrode material type.
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When the spent dialysate is heated to 100°C in a closed loop, organic dialysis products decom-
pose to a gaseous state. For example, thermolysis of urea proceeds according to the following 
Eq. (5):
  (N  H 2  ) 2  CO +  H 2  O  θ>373°K  ⎯ ⟶   (N  H 3  ) 2  C  O 2   Carbonate  ⎯⎯ ⟶  2N  H 3 ↑ + C  O 2 ↑ (5)
where Θ is the thermolysis temperature, °K.
The results of the studies [8] demonstrate that nitrogen-containing components (urea, uric 
acid, and creatinine) elimination rate exponentially depends on the temperature.
Thermal dialysate regenerator functioning can be represented by a sequence of steps. The 
first stage involves the filling of the thermal regenerator with dialysate and its subsequent 
heating up to a given thermolysis temperature Θ. The second stage is the regeneration of 
dialysate. The third stage is cooling the dialysate down and its removal from the thermal 
regenerator.
The results of the experimental testing of the thermal regenerator presented in [6] confirmed 
the possibility of using the proposed method for dialysate regeneration; urea elimination rate 
Figure 6. pH and ions’ concentration dynamics during dialysate regeneration by electrolysis.
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was 2.5–10.0 g/h in temperature range of 160–250°C, but this method was not further devel-
oped due to the significant energy consumption and the need for the thermal reactor to func-
tion at high excess pressures.
Considering all the above, it could be said that combinations of sorption + enzymatic method 
and sorption+ electrolysis are most perspectives to use in WAKs. Some of the current proto-
types are presented below.
4. Prototypes of WAK
4.1. ViWAK PD (Vicenza University, Italy)
The device is implemented in accordance with the scheme a) of Figure 2. The device [7] is 
placed in a vest and is controlled wirelessly by a mobile device. The apparatus includes a 
system for spent dialysate regeneration based on the urease enzyme. The regeneration unit 
REDY (REcirculating DialYsis) includes urease, zirconium phosphate, zirconium oxide and 
activated carbon for the removal of urea, heavy metals, creatinine, uric acid and by-products 
of chemical reactions. The regeneration unit is designed to purify 12l of spent dialysate (about 
a day of continuous operation). ViWAK PD uses a double hollow catheter for intraperitoneal 
infusion of dialysate, which is then purified in an extracorporeal circuit. The device operates 
from an external battery for 10 h, while the mass of the device is about 200 g. The device is also 
equipped with a sterilising filter, a degasser, a pressure sensor and a rotary pump.
The apparatus does not perform ultrafiltration (removal of excess fluid from the body), which 
reduces the applicability of the device in patients with zero residual renal function.
4.2. WAK (University of California, Los Angeles, USA)
Portable hemodialysis apparatus [8] implements HD according to scheme b) of Figure 2. The 
device consists of two sections:
1. A blood transport section in which the patient’s blood moves to the dialyzer along the arte-
rial line and then returns to the patient’s cardiovascular system;
2. The dialysate transport section, where the dialysis solution enters the mass transfer device 
and then moves through the regeneration system, at the same time it is cleared of accu-
mulated toxins and saturated with sodium bicarbonate. The apparatus also has pumps for 
controlling the flow of anticoagulant and for performing ultrafiltration.
The device is made in the form of a belt and weighs 5 kg. The device consists of four pumps, 
powered by external batteries (provide continuous operation for 8 h), and regulate the 
removal and addition of fluids in the circuits through the blood and dialysate. The dialysate 
is continuously regenerated by passing through three containers with sorbents containing 
urease, activated carbon, zirconium oxide and zirconium phosphate (REDY system).
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Initial testing of the device was performed on eight patients, and an average urea removal rate 
of 1.6 mmol/h, creatinine 1.2 mmol/h was obtained.
4.3. SORB (Fresenius Medical Care, Waltham, USA)
The device [9] realises the PD method according to scheme a) of Figure 2. The device is a belt 
with a mass of 2 kg, in which the dialysate moves through a series of sorption containers, 
along hollow fibres, on the outside of which there is a sorbent absorbing phosphate, organic 
substances and ammonium from the volume of dialysate, and urea decomposition by enzy-
matic method (using urease) with subsequent removal of the reaction products.
Among the shortcomings of this device can be identified the lack of ultrafiltration, as well as 
the absorption of calcium and magnesium from the dialysate, which requires the use of an 
infusion pump to return them to the dialysate.
4.4. WABPU (ZITC, Moscow, Russia)
The device [10] implements the PD method according to scheme c) of Figure 2. The device 
is a 3.5 kg backpack containing a hydraulic circuit that realises recirculation and dialysate 
regeneration and an electrical circuit that realises the control of the procedure, the system as 
a whole, and communication with the smartphone displaying user interface. The functional 
diagram of the device is shown in Figure 7.
Figure 7. Functional diagram of WABPU: UV—ultrafiltrate [12].
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Regeneration of the dialysate solution is carried out by sorption of metabolites by activated 
charcoal and electro-oxidation of urea in an electrolytic cell. The combination of the material 
of electrodes and sorbents allows maintaining the pH of the dialysate at a constant level (7.1 
… 7.3), but slightly changes the ion composition, which is solved by the selection of special-
ised sorbents and ion exchange resins. The device includes a control unit, a battery (provides 
continuous operation for 8 h), pump modules, a dialysate regeneration unit, a trunk and a 
smartphone. The regeneration unit includes an electrolyzer, a degasser and two sorption col-
umns with activated carbon. The device was successfully tested on an animal model. Now the 
device is in preparation for clinical trials.
4.5. WAKD (nephron + project, Netherlands)
The apparatus [11] uses a combination of sorption and electrolysis of the spent dialysate [12]. 
The concept of the device was initially based on the method of hemodialysis, but in the last 2 
years, it was changed in favour of peritoneal dialysis. The device is made in the form of a block, 
located on the belt. Management is carried out using a smartphone. The device assumes the 
presence of a special pump for introducing a glucose solution to maintain the concentration of 
the osmotic agent in the dialysate during dialysis to maintain the patient’s fluid balance. The 
hemodialysis-based apparatus underwent preclinical tests on animals. WAKD weighs 3.2 kg, 
but the developers claim about its possible miniaturisation to 2.5 kg.
A comparison of the existing WAK prototypes devices is presented in Table 4.
Name Type Regeneration 
method
Characteristics Current status
ViWAK [7] PD Sorption + urease 0.2 kg, 17 × 8 × 3 cm, 10 h of battery life The prototype was not 
further developed
The WAK [8] HD Sorption + urease 5 kg, on-waist wearable, 8 h of battery 
life, urea removal rate 1.6 mmol/h, 
creatinine 1.2 mmol/h
Pre-clinical trials are 
under way
EO NAIP [10] PD Sorption + 
electrolysis
3.5 kg, backpack, urea removal rate 
1.2 g/h, creatinine 0.3 g/h
Preclinical tests passed
SORB [9] PD Sorption + urease 2 kg, on-waist wearable The prototype was not 
further developed
AWAK [12] PD Sorption + urease 1 kg, shoulder bag or vest, 16 h of 
battery life, expendables exchange 
every 7 or 12 h
Pre-clinical trials are 
under way
WAK-MAN [13] HD Sorption Vest, 24 h of battery life, The prototype was not 
further developed
WAKD [11] HD and PD Sorption + 
electrolysis
3.2 kg, on-waist wearable, up to 30 ml of 
urea clearance
Pre-clinical trials are 
under way
Table 4. Current WAK prototypes.
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Table 4 shows that the current state of development of equipment for artificial blood purifica-
tion allows you to count on their clinical use in the next 2–5 years.
Wearable equipment for artificial blood purification will overcome the shortcomings of exist-
ing apparatus and methods of dialysis and is one of the most promising areas in the field of 
biomedical engineering of artificial organs.
5. General problems of WAK development
Osmotic agents are added to the peritoneal dialysis solution to remove excess fluid from the 
body. They make the solution hyperosmolar in comparison with extracellular fluid, which 
leads to the removal of the liquid through ultrafiltration. The ideal osmotic agent must be 
cheap, biocompatible, with a sufficiently small molecular mass for changing the viscosity of 
the RPD, but with a sufficiently large molecular mass to not be absorbed into the bloodstream. 
The list of potential osmotic agents examined includes glucose, glycerol, xylitol, sorbitol, fruc-
tose, mannitol, gelatine, glucose polymers, polypeptides and dextrans. Most of them turned 
out to be unsuitable due to side effects. Relative success was seen with the use of glycerine, 
amino acids and glucose polymers, but only glucose, glucose polymers and amino acids are 
used in everyday clinical practice.
The main disadvantage of low molecular weight osmotic agents is their rapid absorption, 
resulting in a loss of ultrafiltration speed and metabolic disturbances. Large, loosely absorbed 
osmotic agents theoretically allow the ultrafiltration to last longer. The driving force, in this 
case—the colloid osmotic pressure, is determined to a greater extent by the number of osmoti-
cally active macromolecules than by the osmotic gradient. This means that osmosis can be 
maintained even with the use of peritoneal dialysis solution with osmolarity close in value to 
the osmolarity of extracellular fluid.
6. Conclusion
Development of WAK is held all over the world. The state of the art is that some of them went 
through animal trials and undergo clinical trials. Most probably first commercial WAKs will 
penetrate the market in 2–3 years. However, there is still very much work to be done because 
the tendency is in achieving the performance of native kidney. In the first stage, WAKs must 
be cheaper than HD and PD that will be the major factor to spread them and that will be a very 
good option to raise the number of patients with CKD who receive RRT.
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